ISLAMABAD: On the occasion of World Hepatitis Day, World Health Organisation (WHO) has urged member countries to take rapid action to improve knowledge about the disease, and to increase access to testing and treatment services.
WHO Director-General Dr Margaret Chan said: “The world has ignored hepatitis at its peril. It is time to mobilize a global response to hepatitis on the scale similar to that generated to fight other communicable diseases like HIV/AIDS and tuberculosis.” He said that only one in 20 people with viral hepatitis know they have it. And just one in 100 with the disease is being treated.
Around the world 400 million people are infected with hepatitis B and C, more than 10 times the number of people living with HIV. An estimated 1.45 million people died of the disease in 2013 – up from less than a million in 1990. In May 2016, at the World Health Assembly, 194 governments adopted the first-ever Global Health Sector Strategy on viral hepatitis and agreed to the first-ever global targets. The strategy includes a target to treat 8 million people for hepatitis B or C by 2020.
The longer term aim is to reduce new viral hepatitis infections by 90 per cent and to reduce the number of deaths due to viral hepatitis by 65% by 2030 from 2016 figures. The strategy is ambitious, but the tools to achieve the targets are already in hand. An effective vaccine and treatment for hepatitis B exists. There is no vaccine for hepatitis C but there has been dramatic progress on treatment for the disease in the past few years.
He said the introduction of oral medicines, called direct-acting antivirals, has made it possible to potentially cure more than 90 per cent of patients within 2-3 months. But in many countries, current policies, regulations and medicine prices put the cure out of most people’s reach.
“We need to act now to stop people from dying needlessly from hepatitis,” said Dr Gottfried Hirnschall, WHO’s Director of the HIV/AIDS Department and Global Hepatitis Programme. “This requires a rapid acceleration of access to services and medicines for all people in need.” Some countries, however, are finding ways to get services to the people who need them. These efforts are made easier by the declining price of hepatitis C medicines. Prices are now dropping, particularly in countries that have access to generic drugs.
In 2015, a preliminary analysis estimated that 300,000 people living in low- and middle-income countries had received hepatitis C treatment based on the new direct-acting antivirals.
